Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

PURPOSE: To conduct an updated exploratory analysis of overall survival (OS) with a longer median follow-up of 73.3 months and evaluate the prognostic value of molecular analysis by circulating tumor DNA (ctDNA). PATIENTS AND METHODS: Patients with hormone receptor–positive/human epidermal growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristofanilli, Massimo, Rugo, Hope S., Im, Seock-Ah, Slamon, Dennis J., Harbeck, Nadia, Bondarenko, Igor, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Iwata, Hiroji, O'Leary, Ben, André, Fabrice, Loibl, Sibylle, Bananis, Eustratios, Liu, Yuan, Huang, Xin, Kim, Sindy, Lechuga Frean, Maria Jose, Turner, Nicholas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662922/
https://www.ncbi.nlm.nih.gov/pubmed/35552673
http://dx.doi.org/10.1158/1078-0432.CCR-22-0305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662922/
https://www.ncbi.nlm.nih.gov/pubmed/35552673
http://dx.doi.org/10.1158/1078-0432.CCR-22-0305

Ejemplares similares